In 1960 a Medical Research Council Working Party was set up to examine the suggestion that vitamin B12 might be of value in treating neuroblastoma (Bodian, 1959) . It was agreed that a controlled clinical trial could not be started because such a course would have involved the denial to one group of patients of a potentially valuable yet apparently harmless treatment. Data were, therefore, collected retrospectively from various centres in the United Kingdom so that the results of treatment in children with neuroblastoma who had or who had not received vitamin B12 could be compared.
Method
Questionaries asking for clinical details of children treated for neuroblastoma were sent to 55 hospitals which agreed to co-operate in the study. The answers to the questionaries, amplified by later inquiries about follow-up results, form the basis of this report.
Results
Reports on the clinical course of 134 patients were received but 26 were unsuitable for analysis. In 7 patients a definite diagnosis of neuroblastoma could not be established, in 12 patients information about general treatment was inadequate, and in 3 it was unclear whether vitamin B12 had been given; the remaining 4 died before any medical treatment could be administered.
Sixty-five patients had received treatment with vitamin B12 at some time during their illness and 43 had never been given any such treatment. However, 4 of the treated group had received vitamin B12 only by mouth, and as it has been claimed that to be effective vitamin B12 must be given in large doses (Bodian, 1963) , these 4 were transferred to the control group. The 61 remaining treated patients had all received at least 2,000 ,ug. vitamin B12 by injection during the course of their illness, but at varying intervals after the diagnosis of the tumour. The inclusion in the treated group of individuals who had been given vitamin B12 as a late secondary treatment would clearly have biased the results, and therefore the main comparison was restricted to the 35 whose treatment with vitamin B12 had been started less than one month after the diagnosis had been made and the 47 who received either no vitamin B12 or only oral treatment. In 17 of the remaining 26 the dates of administration of the drug were uncertain, and in 9 it had been given at least one month after diagnosis of the disease. Table I gives the numbers of children who are known to have died and the number who were still alive when last followed up, and their survival time after the diagnosis of neuroblastoma. Only 9 M. J. S. Langman absence of specific treatment. The poor general response of patients with neuroblastoma is clearly illustrated by the survival curve shown in the Fig. Half of all the patients were dead within six months and four-fifths within two years.
